KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Non-Current Assets: 2020-2024

Historic Non-Current Assets for AbCellera Biologics (ABCL) over the last 5 years, with Dec 2024 value amounting to $609.2 million.

  • AbCellera Biologics' Non-Current Assets rose 1.68% to $660.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $660.9 million, marking a year-over-year increase of 1.68%. This contributed to the annual value of $609.2 million for FY2024, which is 1.12% down from last year.
  • Latest data reveals that AbCellera Biologics reported Non-Current Assets of $609.2 million as of FY2024, which was down 1.12% from $616.1 million recorded in FY2023.
  • AbCellera Biologics' Non-Current Assets' 5-year high stood at $616.1 million during FY2023, with a 5-year trough of $192.2 million in FY2020.
  • Moreover, its 3-year median value for Non-Current Assets was $609.2 million (2024), whereas its average is $580.2 million.
  • Per our database at Business Quant, AbCellera Biologics' Non-Current Assets surged by 102.26% in 2021 and then fell by 1.12% in 2024.
  • Yearly analysis of 5 years shows AbCellera Biologics' Non-Current Assets stood at $192.2 million in 2020, then spiked by 102.26% to $388.8 million in 2021, then soared by 32.58% to $515.4 million in 2022, then grew by 19.54% to $616.1 million in 2023, then fell by 1.12% to $609.2 million in 2024.